Effect of Rivastigmine in Electroconvulsive therapy (ECT)-induced cognitive disorders

Phase 3

Recruiting

• Conditions: ECT, Electroconvulsive therapy, Electroshock, ECT-induced Cognitive Disorders, ECT-induced Memory Disorder, Rivastigmine, Cholinesterase Inhibitors, MoCA, ACE, Effect of Rivastigmine on Cognitive Impairment After ECT, Effect of cholinesterase inhibitiors on cognitive impairments after electroconvulsive therapy, effect of Rivastigmine on memory.

• Registration Number: IRCT20200122046225N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

Patients over than 18 years and less than 70 years
Patients with diagnosis of BMD & Schizophrenia who are candidates for ECT
Psychiatric diagnosis of patients based on DSM IV, SCIDP criteria
Patients with refractory treatment and candidate for ECT
Resistance to at least 2 antipsychotics for 6 weeks at a equivalent dose of 1000 mg chlorpromazine
Patients with cognitive decline with electroshock diagnosed by neuroscientist and under cognitive evaluation by ACE, MoCA

Exclusion Criteria

Patients with a history of previous neurologic disease include Stroke and Parkinson's disease
Patients with a history of previous cognitive impairment and dementia
Patients with heart block and arrhythmia
Patients with a history of severe gastrointestinal disorders and gastrointestinal bleeding
History of serious medical illness
present use of substances

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Montreal Cognitive Assessment Score. Timepoint: Before receiving the first ECT session, after receiving the last session and 1 month after the beginning of intervention and finally 3 months after that. Method of measurement: Montreal Cognitive Assessment Test Questionnaire.;Addenbrooke's Cognitive Examination Score. Timepoint: Before receiving the first ECT session, after receiving the last session and 1 month after the beginning of intervention and finally 3 months after that. Method of measurement: Addenbrooke's Cognitive Examination Questionnaire.